Rett syndrome is a pervasive developmental disorder with a variable clinical presentation, which is caused by point mutations or large deletions/duplications in the X-linked methyl-CpG
INTRODUCTION
Rett syndrome (RTT, MIM 312750) is a severe, progressive neurodevelopmental disorder, now classifi ed into pervasive diseases. It is caused by mutations in the X-linked methylCpG-binding protein 2 (MECP2) gene. The syndrome is predominantly found in females, with global prevalence of approximately one per 10 000-15 000 female newborns (1) . Rett syndrome can be diff erentiated into two types: classical and atypical. Typical or classic Rett syndrome is characterized by normal development up to the age of 7 to 18 months. A period of developmental stagnation is followed by rapid vocabulary regression, stereotypic hand movements, and loss of speech and acquired motor skills. In contrast, atypical Rett syndrome refers to a series of patients who do not meet all the criteria, but manifest with some variations in clinical presentation of the disease, character-ized by heterogeneity in the age of onset, severity and clinical course (2) . Point mutations and insertion/deletion variations in the MECP2 gene (Xq28) are reported in approximately 70%-80% of classic Rett syndrome cases (3) and in a much lower percentage of atypical cases (4, 5) . Epilepsy is considered a major problem in all Rett syndrome patients (6) .
CASE REPORT
Our patient was born after an uneventful pregnancy in a family with no apparent disease history, as a fourth child. There were no complications during the perinatal period. Her growth and psychomotor development were normal, except for delayed speech. The fi rst tonic-clonic seizure started at three years of age and were followed by developmental and language delay and deterioration. Landau-Kleffner syndrome was suspected. Because of autism-like behavior, periods of ataxia and hyperventilation with episodes of breath-holding spells, eye-rolling motions and astatic epileptic fi ts, multiple metabolic diseases were excluded by numerous analyses (amino and organic acids, catalytic activities of lysosomal enzymes). No signs of numerical or structural chromosomal changes were found. Electroencephalographic (EEG) records during awake and sleep periods demonstrated focal and paroxysmal discharges. Magnetic resonance imaging (MRI) of the brain was normal and without signs of demyelination. Brain auditory evoked potentials showed bilaterally conduction disturbances through the brain stem with no hearing problems. At the age of 5 years, hand-washing movements were observed, and clinical suspicion of Rett syndrome was confi rmed with identification of a heterozygous novel 25 bp deletion mutation (c.881_905del25) in exon 4 of the MECP2 gene.
Multiple epileptic seizure types resistant to any drug therapy occurred on a daily basis. Antiepileptic drug therapy was started with carbamazepine, and then ethosuximide was added but was soon replaced with valproic acid. Carbamazepine was also omitted and vigabatrin was slowly introduced. Vigabatrin was discontinued and lamotrigine, shortly followed by topiramate, was introduced in therapy. Although the patient is still under this dual drug treatment to improve her EEG, she is suff ering from astatic and tonic seizures every day, especially in the morning. Presently, she has a wide based gait, spastic slow walk and major problems with sleeping. There have been occasional aggression incidents.
DISCUSSION
With case description of this girl we want to emphasize how diff erent genotypes can have atypical phenotypes. The onset of symptoms began much later than usual. At the age of three years, she had her fi rst seizure, while seizures commonly occur at the age of 7 to 18 months (2, 3) . In addition, her ability to walk at the age of 19 is still preserved (3, 5) . In most cases of Rett syndrome, patients lose their ability to walk by the age of 10 years, and have lost it certainly in their late teens (3, 5) . Continuous seizures, often seen in other cases of Rett syndrome (2, (6) (7) (8) , but with resistance to all combinations of antiepileptic drug therapy, is the main problem in this patient. Using standard genetic analysis (2-6), a novel deletion mutation was revealed in exon 4 of the MECP2 gene. The pathogenic mutations in the coding parts of the MECP2 exon 4 have previously been described as more common in Croatian girls (9) .
CONCLUSION
We described a 19-year-old girl with Rett syndrome. The patient had a markedly diff erent clinical presentation of the illness, with epileptic seizures at daily frequency and the ability to walk at the age of 19 years. She was found to be heterozygous for a novel 25 bp deletion mutation in exon 4 (c.881_905del25) of the MECP2 gene. To our knowledge, this mutation has not yet been reported. There is an important discordance between the usual progression of the illness and her current clinical state. A genotype-phenotype correlation is suspected. 
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